BIOCRYST PHARMACEUTICALS, INC. Deferred Tax Liabilities, Gross
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Deferred Tax Liabilities, Gross of $3.58 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-02-26
- 2025-12-31: Deferred Tax Liabilities, Gross $3.58M.
- 2024-12-31: Deferred Tax Liabilities, Gross $3.42M.
- 2023-12-31: Deferred Tax Liabilities, Gross $3.55M.
- 2022-12-31: Deferred Tax Liabilities, Gross $2.24M.
| Period end | Deferred Tax Liabilities, Gross | Deferred Tax Liabilities, Gross as first filed |
|---|---|---|
| 2025-12-31 | $3.58M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $3.42M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $3.55M 10-K · filed 2025-02-25 | |
| 2022-12-31 | $2.24M 10-K · filed 2024-02-27 | |
| 2021-12-31 | $2.13M 10-K · filed 2023-02-27 | |
| 2020-12-31 | $978.00K 10-K · filed 2022-02-28 | |
| 2019-12-31 | $917.00K 10-K · filed 2021-03-01 | |
| 2018-12-31 | $649.00K 10-K · filed 2020-03-13 | |
| 2017-12-31 | $899.00K 10-K · filed 2019-03-14 | |
| 2016-12-31 | $2.09M 10-K · filed 2018-03-12 | |
| 2015-12-31 | $2.67M 10-K · filed 2017-02-27 | |
| 2014-12-31 | $2.29M 10-K · filed 2016-02-26 | -$2.29M 10-K · filed 2015-03-02 |
| 2013-12-31 | -$207.00K 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |